Types of myocardial injury and mid-term outcomes in patients with COVID-19.
Acute Disease
/ epidemiology
Adult
Aged
Aged, 80 and over
COVID-19
/ complications
Chronic Disease
/ epidemiology
Comorbidity
Coronary Artery Disease
/ epidemiology
Female
Heart Failure
/ epidemiology
Humans
Male
Middle Aged
Mortality
/ trends
Myocardial Infarction
/ blood
New York City
/ epidemiology
Outcome Assessment, Health Care
Prognosis
Renal Insufficiency, Chronic
/ epidemiology
Retrospective Studies
SARS-CoV-2
/ genetics
Troponin
/ analysis
COVID-19
Coronavirus
Myocardial injury
Troponin
Journal
European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796
Informations de publication
Date de publication:
16 09 2021
16 09 2021
Historique:
received:
13
07
2021
revised:
30
07
2021
accepted:
03
08
2021
pubmed:
31
8
2021
medline:
25
9
2021
entrez:
30
8
2021
Statut:
ppublish
Résumé
To evaluate the acute and chronic patterns of myocardial injury among patients with coronavirus disease-2019 (COVID-19), and their mid-term outcomes. Patients with laboratory-confirmed COVID-19 who had a hospital encounter within the Mount Sinai Health System (New York City) between 27 February 2020 and 15 October 2020 were evaluated for inclusion. Troponin levels assessed between 72 h before and 48 h after the COVID-19 diagnosis were used to stratify the study population by the presence of acute and chronic myocardial injury, as defined by the Fourth Universal Definition of Myocardial Infarction. Among 4695 patients, those with chronic myocardial injury (n = 319, 6.8%) had more comorbidities, including chronic kidney disease and heart failure, while acute myocardial injury (n = 1168, 24.9%) was more associated with increased levels of inflammatory markers. Both types of myocardial injury were strongly associated with impaired survival at 6 months [chronic: hazard ratio (HR) 4.17, 95% confidence interval (CI) 3.44-5.06; acute: HR 4.72, 95% CI 4.14-5.36], even after excluding events occurring in the first 30 days (chronic: HR 3.97, 95% CI 2.15-7.33; acute: HR 4.13, 95% CI 2.75-6.21). The mortality risk was not significantly different in patients with acute as compared with chronic myocardial injury (HR 1.13, 95% CI 0.94-1.36), except for a worse prognostic impact of acute myocardial injury in patients <65 years of age (P-interaction = 0.043) and in those without coronary artery disease (P-interaction = 0.041). Chronic and acute myocardial injury represent two distinctive patterns of cardiac involvement among COVID-19 patients. While both types of myocardial injury are associated with impaired survival at 6 months, mortality rates peak in the early phase of the infection but remain elevated even beyond 30 days during the convalescent phase.
Identifiants
pubmed: 34458912
pii: 6359060
doi: 10.1093/ehjqcco/qcab053
doi:
Substances chimiques
Troponin
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
438-446Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.